Coeliac disease.
Glissen Brown JR, Singh P.
Paediatr Int Child Health. 2019 Feb;39(1):23-31. doi: 10.1080/20469047.2018.1504431. Epub 2018 Aug 13.
Autoimmune Polyendocrine Syndromes.
Husebye ES, Anderson MS, Kämpe O.
N Engl J Med. 2018 Mar 22;378(12):1132-1141. doi: 10.1056/NEJMra1713301.
IPEX Syndrome: Genetics and Treatment Options.
Ben-Skowronek I.
Genes (Basel). 2021 Feb 24;12(3):323. doi: 10.3390/genes12030323.
Immunogenetics of type 1 diabetes mellitus.
Morran MP, Vonberg A, Khadra A, Pietropaolo M.
Mol Aspects Med. 2015 Apr;42:42-60. doi: 10.1016/j.mam.2014.12.004. Epub 2015 Jan 8.
Incretins beyond type 2 diabetes.
Mathieu C, Ahmadzai I.
Diabetologia. 2023 Oct;66(10):1809-1819. doi: 10.1007/s00125-023-05980-x. Epub 2023 Aug 8.
Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Nan J, Wang D, Zhong R, Liu F, Luo J, Tang P, Song X, Zhang L.
Prim Care Diabetes. 2024 Feb;18(1):17-24. doi: 10.1016/j.pcd.2023.10.010. Epub 2023 Nov 18.
Gastrointestinal symptoms in pediatric patients with type 1 diabetes mellitus.
Selbuz S, Buluş AD.
J Pediatr Endocrinol Metab. 2020 Feb 25;33(2):185-190. doi: 10.1515/jpem-2019-0350.
Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H, Smith KH, Bramlage P, Minguet J.
Diabet Med. 2018 Aug;35(8):1037-1048. doi: 10.1111/dme.13645. Epub 2018 Jul 3.
The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials.
Zhou F, Du N, Zhou L, Wang C, Ren H, Sun Q.
Front Endocrinol (Lausanne). 2022 Sep 26;13:968478. doi: 10.3389/fendo.2022.968478. eCollection 2022.
Fulminant type 1 diabetes mellitus in pregnancy.
Li CY, Li Y, You ZY, Liu YR, Wang YJ, Mu T, Zhao CZ, Yi ZM, Zhang YW.
Braz J Med Biol Res. 2020;53(9):e9633. doi: 10.1590/1414-431x20209633. Epub 2020 Jul 17.
